Publications by authors named "E Vijverberg"
Article Synopsis
- Behavioral variant frontotemporal dementia (bvFTD) leads to significant changes in personality and behavior, but there’s a lack of consensus on effective drug treatments despite high symptom burden for patients and caregivers.
- A survey of 48 experts in dementia treatment identified that disinhibition and compulsive behaviors are the primary symptoms targeted, with suggested medications including atypical antipsychotics and SSRIs.
- The findings indicate varied treatment approaches among professionals, highlighting the need for more research to develop consensus on effective pharmacological strategies for managing bvFTD symptoms.
Background: CT1812 is a first-in-class, sigma-2 receptor ligand, that prevents and displaces binding of amyloid beta (Aβ) oligomers. Normalization of quantitative electroencephalography (qEEG) markers suggests that CT1812 protects synapses from Aβ oligomer toxicity.
Objectives: Evaluate CT1812 impact on synaptic function using qEEG measurements.
Trajectories of behavior and social cognition in behavioral variant frontotemporal dementia and primary psychiatric disorders: A call for better operationalization of socioemotional changes.
Eur J Neurol
December 2024
Background And Purpose: Behavioral variant frontotemporal dementia (bvFTD) and primary psychiatric disorders (PPD), such as mood, psychotic, and autism spectrum disorders, share similar clinical characteristics of behavior and social cognition. Better understanding of clinical progression in bvFTD and PPD is essential for adequate disease monitoring and trial design.
Methods: In this longitudinal study (N = 89), patients with bvFTD and PPD with at least one follow-up assessment were included from the Social Brain Project of the Alzheimer Center Amsterdam.
Pooling Alzheimer's disease clinical trial data to develop personalized medicine approaches is easier said than done: A proof-of-principle study and call to action.
Alzheimers Dement (N Y)
August 2024
Unlabelled: With the advent of the first generation of disease-modifying treatments for Alzheimer's disease, it is clearer now more than ever that the field needs to move toward personalized medicine. Pooling data from past trials may help identify subgroups most likely to benefit from specific treatments and thus inform future trial design. In this perspective, we report on our effort to pool data from past Alzheimer's disease trials to identify patients most likely to respond to different treatments.
View Article and Find Full Text PDFArticle Synopsis
- The study investigates the relationship between traumatic brain injury (TBI) and Alzheimer's disease (AD) by comparing AD patients with and without a history of TBI, focusing on various biomarkers in their cerebrospinal fluid (CSF).
- Researchers found no significant differences in baseline CSF biomarker levels or cognitive decline between the two groups of AD patients, suggesting that TBI may not directly affect AD progression.
- However, TBI occurring more than five years prior was linked to higher levels of specific biomarkers (NPTX2 and a trend for SNAP25), indicating possible long-term synaptic dysfunction effects when TBI occurs before the onset of AD.